Oragenics, Inc.
OGEN
Rank in Stocks
#32445
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on... Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option. Beyond its infectious disease focus, Oragenics also has other experimental treatments under development, including LPT3-04, targeting weight loss, and SMaRT Replacement Therapy, a topical solution aimed at preventing dental cavities. Strategic alliances are also a part of its operations. This includes a licensing deal with Noachis Terra Inc. for patents and biological resources related to pre-fusion coronavirus spike proteins. Additionally, Oragenics is collaborating with Precigen, Inc. and ILH Holdings, Inc. on the advancement and market introduction of MU1140 and its associated compounds. Established in 1996, the company, formerly known as Oragen, Inc., maintains its headquarters in Tampa, Florida.
Share Price
$0.3548
Last synced: 2026-11-09
Market Cap
$1.60M
Change (1 day)
1.62%
Change (1 year)
-68.60%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Oragenics, Inc. (OGEN)
Category
Healthcare
EPS for Oragenics, Inc. (OGEN)
EPS as of June 2026 TTM: $-3.58
According to Oragenics, Inc.'s latest financial reports, its current EPS (TTM) is $-3.58. At the end of 2025 the company had an EPS of $-4.56, a decrease compared to its 2024 EPS of $-1.60.
EPS history for Oragenics, Inc. from 2003 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-3.58 | -21.49% |
| 2025 | $-4.56 | 185.00% |
| 2024 | $-1.60 | -82.57% |
| 2023 | $-9.18 | 29.11% |
| 2022 | $-7.11 | -12.11% |
| 2021 | $-8.09 | -71.16% |
| 2020 | $-28.05 | 26.92% |
| 2019 | $-22.10 | -51.56% |
| 2018 | $-45.62 | -44.36% |
| 2017 | $-81.99 | -13.10% |
| 2016 | $-94.35 | -50.86% |
| 2015 | $-192.00 | 99.83% |
| 2014 | $-96.08 | -71.32% |
| 2013 | $-335.02 | -24.35% |
| 2012 | $-442.86 | -45.04% |
| 2011 | $-805.84 | -5.17% |
| 2010 | $-849.77 | -16.69% |
| 2009 | $-1.02K | -50.51% |
| 2008 | $-2.06K | 86.41% |
| 2007 | $-1.11K | -37.15% |
| 2006 | $-1.76K | -32.05% |
| 2005 | $-2.59K | -1.76% |
| 2004 | $-2.64K | 74.53% |
| 2003 | $-1.51K | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -537.43% |
US
|
|
| $-7.07 | 97.49% |
US
|
|
| $-5.29 | 47.77% |
AU
|
|
| $12.88 | -459.78% |
BE
|
|
| $21.56 | -702.23% |
NL
|
Questions about Oragenics, Inc.'s earnings per share (EPS)
What is Oragenics, Inc.'s earnings per share (EPS)?
Oragenics, Inc.'s earnings per share (EPS) over the last twelve months is $-3.58, as of Jun 2026.
What was Oragenics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Oragenics, Inc.'s earnings per share (EPS) was $-4.56, compared with $-1.60 in 2024.
How has Oragenics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Oragenics, Inc.'s earnings per share (EPS) was highest in 2024 ($-1.60) and lowest in 2020 ($-28.05).
How does Oragenics, Inc.'s earnings per share (EPS) compare with similar companies?
Oragenics, Inc.'s earnings per share (EPS) ($-3.58) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.